[
  {
    "ts": null,
    "headline": "US Weighs Trump-Branded Website to Help Shop for Cheaper Drugs",
    "summary": "The initiative is part of Trump’s demands that drugmakers reduce their prices to align them with what other developed countries pay, according to the people, who spoke on condition of anonymity to discuss plans that are not yet public.  The proposed website would allow patients to search for specific medicines and be connected with platforms that sell them, the people said.",
    "url": "https://finnhub.io/api/news?id=0e750c560c0ea09bf3dc6730b90444afd04249631e5b78e5380f5bdb5e0db388",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758314575,
      "headline": "US Weighs Trump-Branded Website to Help Shop for Cheaper Drugs",
      "id": 136823430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The initiative is part of Trump’s demands that drugmakers reduce their prices to align them with what other developed countries pay, according to the people, who spoke on condition of anonymity to discuss plans that are not yet public.  The proposed website would allow patients to search for specific medicines and be connected with platforms that sell them, the people said.",
      "url": "https://finnhub.io/api/news?id=0e750c560c0ea09bf3dc6730b90444afd04249631e5b78e5380f5bdb5e0db388"
    }
  },
  {
    "ts": null,
    "headline": "Boost Your Portfolio With These Top-Ranked ETFs",
    "summary": "With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.",
    "url": "https://finnhub.io/api/news?id=c3a16726b91d0b08996b35a01e7c94129896f7eb5a7275e118581c668933c7f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758301380,
      "headline": "Boost Your Portfolio With These Top-Ranked ETFs",
      "id": 136820651,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.",
      "url": "https://finnhub.io/api/news?id=c3a16726b91d0b08996b35a01e7c94129896f7eb5a7275e118581c668933c7f2"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?",
    "summary": "NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.",
    "url": "https://finnhub.io/api/news?id=9e19d06dc8120ac1e1966b1b9b6b5c5ed8ffd0a7fa2a4a7a5f750b8f24368dc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758297060,
      "headline": "Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?",
      "id": 136820653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.",
      "url": "https://finnhub.io/api/news?id=9e19d06dc8120ac1e1966b1b9b6b5c5ed8ffd0a7fa2a4a7a5f750b8f24368dc9"
    }
  },
  {
    "ts": null,
    "headline": "This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?",
    "summary": "Eli Lilly's initiative could make the company even more successful than it already is.",
    "url": "https://finnhub.io/api/news?id=6ab2d21f107f6ed866793cba0ffb330647081520a2e8fea0a633816c362ec67c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758290400,
      "headline": "This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?",
      "id": 136818160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's initiative could make the company even more successful than it already is.",
      "url": "https://finnhub.io/api/news?id=6ab2d21f107f6ed866793cba0ffb330647081520a2e8fea0a633816c362ec67c"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Eli Lilly Be in 3 Years?",
    "summary": "With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.",
    "url": "https://finnhub.io/api/news?id=d5420a8d9aaf500cb381ce5ca9a433d7ac5defdb314be82aa58c69313413f3b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758287700,
      "headline": "Where Will Eli Lilly Be in 3 Years?",
      "id": 136818161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.",
      "url": "https://finnhub.io/api/news?id=d5420a8d9aaf500cb381ce5ca9a433d7ac5defdb314be82aa58c69313413f3b3"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Don't Be Deterred By Outlook Downgrades",
    "summary": "Novo Nordisk A/S's outlook downgrades are concerning, but strong growth potential and positive study results make NVO stock worth considering. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=38ebf990130819659eedffd8d7983982a7b210b2ebb5af5d51dac44b47ac4dc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758285426,
      "headline": "Novo Nordisk: Don't Be Deterred By Outlook Downgrades",
      "id": 136820402,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305436/image_2158305436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S's outlook downgrades are concerning, but strong growth potential and positive study results make NVO stock worth considering. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=38ebf990130819659eedffd8d7983982a7b210b2ebb5af5d51dac44b47ac4dc2"
    }
  },
  {
    "ts": null,
    "headline": "Why Shares in Novo Nordisk Soared This Week",
    "summary": "Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.",
    "url": "https://finnhub.io/api/news?id=c049161c9685b1cb07b5eedca4b1ec9c8732c78a10846b90e46175cb202e7384",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758284520,
      "headline": "Why Shares in Novo Nordisk Soared This Week",
      "id": 136818162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.",
      "url": "https://finnhub.io/api/news?id=c049161c9685b1cb07b5eedca4b1ec9c8732c78a10846b90e46175cb202e7384"
    }
  },
  {
    "ts": null,
    "headline": "14 Press Releases You Need to See This Week",
    "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
    "url": "https://finnhub.io/api/news?id=ece8ee3697dd682c4fd90bb4158688edcb8f4f0dd7e5f7a29e110acab3cbd207",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758279720,
      "headline": "14 Press Releases You Need to See This Week",
      "id": 136818163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
      "url": "https://finnhub.io/api/news?id=ece8ee3697dd682c4fd90bb4158688edcb8f4f0dd7e5f7a29e110acab3cbd207"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months",
    "summary": "Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.",
    "url": "https://finnhub.io/api/news?id=e4c1751c74c62a468091bb81fd920749ed606a84f959380eef0f7e2e1bea3955",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758274800,
      "headline": "Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months",
      "id": 136818164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.",
      "url": "https://finnhub.io/api/news?id=e4c1751c74c62a468091bb81fd920749ed606a84f959380eef0f7e2e1bea3955"
    }
  }
]